<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04327063</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2019-04</org_study_id>
    <nct_id>NCT04327063</nct_id>
  </id_info>
  <brief_title>MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery</brief_title>
  <official_title>A Double-blind Randomized Trial of Interpectoral Nerve Block (Pecs 1 and 2) With Ropivacaine Versus Placebo Before Breast Cancer Surgery: Effects on Acute Postoperative Pain. (MIRs 04)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the effect of ropivacaine versus placebo pectoral nerve block (Pecs 1 and 2) on acute&#xD;
      pain after tumorectomy plus sentinel lymph node dissection on one day surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before surgery, the 3rd interpectoral space will be identified. After aspiration, half of the&#xD;
      solution of Ropivacaine 5 mg/ml not exceeding 3 mg/kg of maximal dose and 30 ml of maximal&#xD;
      volume or saline (not exceeding 30 ml of maximal volume) will be injected into the&#xD;
      interpectoral space underneath the pectoralis major muscle for the Pecs 1 block. The other&#xD;
      half of the solution will be injected above the serratus anterior muscle at the third rib.&#xD;
&#xD;
      Evaluation of the percentage of patients treated with step 2 or 3 analgesics during the three&#xD;
      postoperative hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Anticipated">December 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 4, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the effect of ropivacaine versus placebo pectoral nerve block (Pecs 1 and 2) on acute pain after tumorectomy plus sentinel lymph node dissection on one day surgery</measure>
    <time_frame>3 hours</time_frame>
    <description>Percentage of patients treated with step 2 or 3 analgesics during the first three postoperative hours after tumorectomy plus sentinel lymph node dissection, between the group with Ropivacaïne and the group with placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of acute pain at rest and after shoulder movement until 48 postoperative hours</measure>
    <time_frame>48 hours</time_frame>
    <description>VAS Scale (0 to 10 : 0 = no pain and 10 = Worst pain possible) at rest and after shoulder movement every 30 minutes during the first three postoperative hours in the PACU and the day surgery unit and then at home every 6 hours for the first 48 postoperative hours .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of acute pain until 48 postoperative hours</measure>
    <time_frame>48 hours</time_frame>
    <description>Brief Pain Inventory Questionnaires at 48 hours will be collected with VAS Scale (0 to 10 : 0 = no pain and 10 = Worst pain possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of patient's satisfaction on pain management</measure>
    <time_frame>48 hours</time_frame>
    <description>Scale of satisfaction ( 0 to 10 : 0 = very bad and 10 = excellent) of the pain management at 48 post-operative hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Remifentanil consumption during anesthesia</measure>
    <time_frame>3 hours</time_frame>
    <description>Total dose of Remifentanil during anesthesia for a bispectral index between 40-60 or Analgesia Nociception Index (ANI) &gt; 60%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of analgesic consumption during the first 48 postoperative hours</measure>
    <time_frame>48 hours</time_frame>
    <description>Consumption of Ketoprofene in systematic, Paracetamol if VAS&gt;3 and Tramadol if analgesia is not enough during 48 postoperative hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the incidence of nausea and vomiting during the first 48 postoperative hours</measure>
    <time_frame>48 hours</time_frame>
    <description>Incidence of nausea and vomiting during the first 48 postoperative hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of complications of Pecs during 48 postoperative hours</measure>
    <time_frame>48 hours</time_frame>
    <description>Complications of Pecs block: pneumothorax, nerve injury, hypotension, vascular puncture and systemic toxicity of local anaesthetic (seizures, etc.) collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the incidence of serious adverse events during 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Number of serious adverse events during 30 days after Pecs administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">182</enrollment>
  <condition>Malignant Neoplasm of Breast</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline (30 mL maximum)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaïne</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ropivacaïne 5 mg/mL (not to exceed 3 mg/kg and 30 ml of maximal volume)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Injection of the solution of Saline not exceeding 30 mL of maximal volume.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NA Cl 0.9%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Dilution of Ropivacaine 7.5 mg/ml to 5 mg/ml not to exceed 3 mg/kg of maximal dose and 30 ml of maximal volume</description>
    <arm_group_label>Ropivacaïne</arm_group_label>
    <other_name>Naropeine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women with non-metastatic invasive breast carcinoma or breast carcinoma in situ&#xD;
             treated by breast-conserving surgery (tumorectomy) with sentinel node technique on one&#xD;
             day surgery.&#xD;
&#xD;
          2. Age between 18 and 85 years.&#xD;
&#xD;
          3. ASA class 1, 2 or 3&#xD;
&#xD;
          4. Signed informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ongoing neoplasm or history of neoplasm other than breast cancer with the exception&#xD;
             of: basal cell carcinoma, cervical carcinoma in situ, other treated cancer that has&#xD;
             not relapsed during the 5 years preceding inclusion in the trial.&#xD;
&#xD;
          2. Axillary dissection planned during surgery planning&#xD;
&#xD;
          3. All bilateral surgery the day of Pecs administration&#xD;
&#xD;
          4. Metastatic breast carcinoma at diagnosis (M1).&#xD;
&#xD;
          5. Allergy to local anesthetics and morphine.&#xD;
&#xD;
          6. Use of analgesics during the 12 hours preceding the surgical procedure.&#xD;
&#xD;
          7. History of ipsilateral surgery during the previous 6 months.&#xD;
&#xD;
          8. History of substance abuse.&#xD;
&#xD;
          9. Pregnant woman or breastfeeding.&#xD;
&#xD;
         10. Subjects deprived of their liberty or under guardianship (including temporary&#xD;
             guardianship).&#xD;
&#xD;
         11. Subjects no covered by social security scheme&#xD;
&#xD;
         12. Experiencing any psychiatric condition or major cognitive impairment that may hamper&#xD;
             completion of self-reported questionnaires.&#xD;
&#xD;
        There is no prohibition for people to take part simultaneously in another search and there&#xD;
        is no exclusion cause at the end of the research period&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre FUMOLEAU, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aline ALBI-FELDZER, MD</last_name>
    <phone>+33 1 47 11 15 15</phone>
    <email>aline.albi-feldzer@curie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Sophie PLISSONNIER</last_name>
    <phone>+33 1 47 11 23 78</phone>
    <email>drci.promotion@curie.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume GAYRAUD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume GAYRAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aline ALBI-FELDZER, MD</last_name>
    </contact>
    <investigator>
      <last_name>ALBI-FELDZER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrien LEMOINE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Adrien LEMOINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien RAFT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julien RAFT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surgery conservative</keyword>
  <keyword>Nerve block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

